News

The new deal extends and expands the companies’ previous three-year agreement from 2009. BioSeek will expand the use of its BioMAP platform to evaluate Merck small molecule compounds

As per the agreement, the term of the development and marketing agreement has been extended from July 2016 to March 2021 and certain financial terms, such as co-promotion

The development and delivery of prototype formulations met the pre-specified attributes under its agreement to license Acuform technology and data to Boehringer Ingelheim. Depomed and Boehringer Ingelheim have

Optimer is eligible to receive a one-time, up-front cash payment of $20m and additional cash payments of up to $70m upon the achievement of certain regulatory and commercial

The grant is from the Eunice Kennedy Shriver National Institute of Child Health & Human Development. PLx Pharma and UTHealth are working to reduce the GI toxicity of

The trial was designed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide. The study met its primary end-point,

The collaboration aims to expand the footprint of Intelsius and its core strategy of offering products globally with local supply. Intelsius CEO David Walsh said the company’s partnership

Omontys injection is a synthetic, pegylated, peptide-based erythropoiesis stimulating agent (ESA). Nektar provides its partner Affymax with its proprietary PEGylation technology for use in Omontys. Two Phase 3

The goal of Compugen Inc., a wholly owned subsidiary of Compugen Ltd., is to translate the growing portfolio of novel mAb targets being discovered and validated by the